- Home
- BGLC vs APVO Comparison
BGLC vs APVO Comparison
Compare BGLC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- APVO
- Stock Information
- Founded
- BGLC 2017
- APVO 2016
- Country
- BGLC Malaysia
- APVO United States
- Employees
- BGLC N/A
- APVO N/A
- Industry
- BGLC Medical Specialities
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- APVO Health Care
- Exchange
- BGLC Nasdaq
- APVO Nasdaq
- Market Cap
- BGLC 5.0M
- APVO 4.1M
- IPO Year
- BGLC N/A
- APVO N/A
- Fundamental
- Price
- BGLC $2.71
- APVO $3.23
- Analyst Decision
- BGLC
- APVO Strong Buy
- Analyst Count
- BGLC 0
- APVO 1
- Target Price
- BGLC N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- BGLC 69.9K
- APVO 6.6M
- Earning Date
- BGLC 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- BGLC N/A
- APVO N/A
- EPS Growth
- BGLC N/A
- APVO N/A
- EPS
- BGLC N/A
- APVO N/A
- Revenue
- BGLC $9,265,870.00
- APVO N/A
- Revenue This Year
- BGLC N/A
- APVO N/A
- Revenue Next Year
- BGLC N/A
- APVO N/A
- P/E Ratio
- BGLC N/A
- APVO N/A
- Revenue Growth
- BGLC N/A
- APVO N/A
- 52 Week Low
- BGLC $2.01
- APVO $2.81
- 52 Week High
- BGLC $8.40
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- BGLC 43.64
- APVO 34.28
- Support Level
- BGLC $2.60
- APVO $2.81
- Resistance Level
- BGLC $3.06
- APVO $13.11
- Average True Range (ATR)
- BGLC 0.21
- APVO 1.10
- MACD
- BGLC -0.06
- APVO 0.30
- Stochastic Oscillator
- BGLC 16.27
- APVO 4.08
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.